Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- Phase I Combination Ixabepilone + Cisplatin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination Ixabepilone + Cisplatin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00832117).
- Phase I Combination w/ Epirubicin: Complete Statistical AnalysisIndependent statistical analysis of Phase I Combination w/ Epirubicin: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00322374).
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.: Complete Statistical AnalysisIndependent statistical analysis of Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide: Complete Statistical AnalysisIndependent statistical analysis of Phase I Dose-Escalation Study Of Azacitidine In Combination With Temozolomide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00629343).
- Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3): Complete Statistical AnalysisIndependent statistical analysis of Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity: Complete Statistical AnalysisIndependent statistical analysis of Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) Followed by Ipilimumab in Advanced Metastatic Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Intravenous Lipotecan® (TLC388 HCl for Injection) in Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I Study of OPC-61815: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of OPC-61815: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03510663).
- Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study Of The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Multiple Intravenously Administered Doses Of PF-04236921 In Patients With Rheumatoid Arthritis: primary endpoint results, effect estimate with…
- Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C: Complete Statistical AnalysisIndependent statistical analysis of Phase I Study of the Safety, Tolerability, PK & PD of Lomitapide in Japanese and Caucasian Subjects With Elevated LDL-C: primary endpoint results, effect estimate with confidence interval,…
- Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): Complete Statistical AnalysisIndependent statistical analysis of Phase I Study: Stop Smoking Therapy for Ontario Patients (STOP): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00356993).
- Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02047500).
- Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers: Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial Evaluating the Pharmacokinetics of Single Ascending Oral Doses of IRL757 in Healthy Elderly Volunteers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase I Trial of BI 836845 for Various Solid Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I Trial of BI 836845 for Various Solid Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01403974).
- Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I-II Everolimus and Sorafenib in Recurrent High-Grade Gliomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01434602).
- Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients: Complete Statistical AnalysisIndependent statistical analysis of Phase I, Open Label Dose Escalation Study to Evaluate Safety of iHIVARNA-01 in Chronically HIV-infected Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I/II Calcitriol in Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Calcitriol in Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00794547).
- Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Eval Safety & Prelim Activity Nivolumab Comb W/Vorolanib Pts W/Refractory Thoracic Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib.: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of OPB-31121 in Patients With Progressive Hepatocellular Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of Pentostatin Combined With Tacrolimus and Mini-Methotrexate for GVHD Prevention After MUD BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD): Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Study of PRO044 in Duchenne Muscular Dystrophy (DMD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01037309).
- Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta “Trap”/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT): Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced…
- Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes: Complete Statistical AnalysisIndependent statistical analysis of Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02240706).
- Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib and Phase II Studies of MK-3475 in Combination + for Renal Cell Carcinoma:: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL: primary endpoint results,…
- Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/2a Drug-drug Interaction Study of a Combination of 45mg Dextromethorphan With 105 mg Bupropion: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors: primary endpoint results, effect estimate with confidence…
- Phase IIIndependent statistical analysis of Electrical Stimulation for Critically Ill Post-Covid-19 Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05198466).
- Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03023722).
- Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors: Complete Statistical AnalysisIndependent statistical analysis of Phase II Capecitabine, Oxaliplatin & Bevacizumab for Metastatic / Unresectable Neuroendocrine Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of Phase II Clinical Trial of Gemcitabine and Doxil® for Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): Complete Statistical AnalysisIndependent statistical analysis of Phase II Copanlisib in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02391116).
- Phase II Dasatinib Study in Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dasatinib Study in Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00546104).
- Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: Complete Statistical AnalysisIndependent statistical analysis of Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…